Achieve Life Sciences is a specialty pharmaceutical company dedicated to combating the global smoking epidemic and supporting smoking cessation. Despite having medications for decades, smoking still poses a significant public health threat, with one-third of cancer deaths in the US attributed to cigarette smoking. Current treatments have proven ineffective, and there have been no new FDA-approved smoking cessation treatments since 2006.

Introducing cytisinicline, a potential game-changer derived from natural sources like the laburnum tree seeds. It is a new treatment for smoking cessation and nicotine addiction. In recent trials, cytisinicline has shown promising results in helping even highly dependent smokers quit with minimal side effects.

It binds to nicotine receptors, reducing withdrawal symptoms and satisfaction associated with smoking. Moreover, it has a lower likelihood of causing side effects like nausea and vomiting. Achieve Life Sciences aims to make cytisinicline widely available as a treatment option for nicotine addiction.

Stay updated with the latest announcements and developments from Achieve as they strive to revolutionize smoking cessation